PCL Retention Versus Sacrifice During Total Knee Replacement With a Medial Pivot Prosthesis

September 24, 2026 updated by: Theodoros Mylonas, University of Thessaly

Retention vs Sacrifice of PCL in TKA With a Medial Pivot Prosthesis: a Prospective, Randomized Trial.

otal knee replacement is a common treatment for patients with severe knee osteoarthritis when non-surgical treatments no longer provide adequate relief. During total knee replacement, surgeons may either preserve or remove the posterior cruciate ligament (PCL), a ligament located inside the knee. Both approaches are used in clinical practice, but the effect of PCL preservation or removal when using a medial-pivot knee prosthesis is not fully established.

This study will compare two surgical approaches in patients undergoing total knee replacement with the same medial-pivot prosthesis. Participants will be randomly assigned to either PCL retention or PCL sacrifice during surgery.

The main purpose of the study is to determine whether retaining or removing the PCL affects how patients perceive and function with their artificial knee. The primary outcome will be the Forgotten Joint Score-12 (FJS-12) at 24 months after surgery, which assesses how much patients are aware of their artificial knee during everyday activities. Other outcomes will include knee function, pain, range of motion, stability, patient satisfaction, complications, and radiographic findings.

The study hypothesis is that there may be a difference in patient-reported outcomes between PCL retention and PCL sacrifice when a medial-pivot knee prosthesis is used. Participants will be evaluated before surgery and at 3, 6, 12, and 24 months after surgery.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

60

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Thessaly
      • Larissa, Thessaly, Greece, 41500
        • University Hospital of Larissa

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

50 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

Age 50 to 85 years. Symptomatic end-stage osteoarthritis of the knee, confirmed clinically and radiographically.

Failure of conservative treatment for knee osteoarthritis. Suitable candidate for primary total knee arthroplasty. Able to participate in and complete the planned postoperative follow-up schedule

Exclusion Criteria:

Previous surgery on the affected knee. Inflammatory arthritis. Active infection. Severe lower-limb deformity greater than 15 degrees. Neurological disease affecting lower-limb function.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: PCL retention

Participants randomized to this arm will undergo primary total knee arthroplasty using a medial-pivot knee prosthesis with retention of the posterior cruciate ligament (PCL).

Participants randomized to this arm will undergo primary total knee arthroplasty using a medial-pivot knee prosthesis (MicroPort Evolution) with retention of the posterior cruciate ligament (PCL). The procedure will be performed according to the standardized surgical technique used by the Orthopaedic Department.

Active Comparator: PCL sacrifice

Participants randomized to this arm will undergo primary total knee arthroplasty using the same medial-pivot knee prosthesis, with sacrifice (removal) of the posterior cruciate ligament (PCL).

Participants randomized to this arm will undergo primary total knee arthroplasty using a medial-pivot knee prosthesis (MicroPort Evolution) with sacrifice of the posterior cruciate ligament (PCL). The procedure will be performed according to the standardized surgical technique used by the Orthopaedic Department.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Forgotten Joint Score-12 (FJS-12) at 24 Months After Total Knee Arthroplasty
Time Frame: 24 months after total knee arthroplasty
24 months after total knee arthroplasty

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Knee Society Score (KSS) at 24 Months After Total Knee Arthroplasty
Time Frame: 24 months after total knee arthroplasty

Assessment of knee function using the Knee Society Score

24 months after total knee arthroplasty
Oxford Knee Score (OKS) at 24 Months After Total Knee Arthroplasty
Time Frame: 24 months after total knee arthroplasty

Assessment of patient-reported knee function using the Oxford Knee Score.

24 months after total knee arthroplasty
Change From Baseline in Knee Range of Motion at 24 Months After Total Knee Arthroplasty
Time Frame: Baseline and 24 months after total knee arthroplasty

Assessment of change in knee range of motion from the preoperative baseline.

Baseline and 24 months after total knee arthroplasty

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2023

Primary Completion (Actual)

September 1, 2026

Study Completion (Actual)

September 24, 2026

Study Registration Dates

First Submitted

September 24, 2026

First Submitted That Met QC Criteria

September 24, 2026

First Posted (Actual)

September 30, 2026

Study Record Updates

Last Update Posted (Actual)

September 30, 2026

Last Update Submitted That Met QC Criteria

September 24, 2026

Last Verified

September 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • 11/06/2026-27262

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.